NCT07227467 Prospective Assessments Following Immediate Lymphatic Reconstruction
| NCT ID | NCT07227467 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Chicago |
| Condition | Lymphatic Reconstruction |
| Study Type | OBSERVATIONAL |
| Enrollment | 100 participants |
| Start Date | 2025-12-01 |
| Primary Completion | 2030-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 100 participants in total. It began in 2025-12-01 with a primary completion date of 2030-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Immediate lymphatic reconstruction (ILR) is a novel surgical approach performed at the time of initial lymph node dissection with the goal of preventing lymphedema.(Chang et al. 2020) It involves the identification of lymphatic channels that are transected after lymph node dissection and microsurgical anastomosis of one or more lymphatic channel with a local recipient vein to re-direct upper extremity lymphatic drainage. Although ILR carries significant promise in prevention of lymphedema, there is a lack of high-level evidence supporting its efficacy because it is a novel surgical technique that is only offered at a few centers and not routinely covered by insurance carriers yet. The University of Chicago Comprehensive Cancer Center (UCCCC) is one of the busiest microsurgery centers performing this procedure, and, as a Lymphedema Center of Excellence, is in a unique position to investigate the efficacy of ILR in preventing lymphedema. In addition, the University has access to a world class microbiome research facility and colleagues. To our knowledge, there is no information on the skin microbiome of the axilla in patients undergoing treatment for breast cancer or those at risk for developing lymphedema. Further exploratory studies such as this in a diverse patient population may lead to practice changing research in our approach to lymphedema management and prevention.
Eligibility Criteria
Inclusion Criteria: potential candidates for ILR based on possible nodal involvement assessed preoperatively. Exclusion Criteria: * Individuals who are not eligible for ILR based on possible nodal involvement assessed preoperatively.
Contact & Investigator
Summer Hanson, MD, PhD, FACS
PRINCIPAL INVESTIGATOR
University of Chicago
Frequently Asked Questions
Who can join the NCT07227467 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Lymphatic Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07227467 currently recruiting?
Yes, NCT07227467 is actively recruiting participants. Contact the research team at sehanson@bsd.uchicago.edu for enrollment information.
Where is the NCT07227467 trial being conducted?
This trial is being conducted at Chicago, United States.
Who is sponsoring the NCT07227467 clinical trial?
NCT07227467 is sponsored by University of Chicago. The principal investigator is Summer Hanson, MD, PhD, FACS at University of Chicago. The trial plans to enroll 100 participants.